A groundbreaking phase 1 clinical trial has documented remarkable efficacy data for VERVE-102, a gene-editing therapy for severe hypercholesterolemia. At the maximum tested dose of 0.6 mg/kg, participants achieved an 84% reduction in LDL cholesterol levels by day 180—a magnitude of benefit unmatched by conventional pharmaceutical interventions.
The dose-response relationship was clear and consistent: medium-dose recipients achieved 55% reduction, while low-dose participants saw 39% reduction, compared to 2% in the placebo group. These results underscore the therapy’s potency and the precision of base-editing technology in modifying gene expression.
The 10 enrolled patients had baseline LDL cholesterol levels exceeding 70 mg/dL despite maximum tolerated statin therapy, representing a treatment-resistant population with substantial cardiovascular risk. No serious adverse events were attributed to VERVE-102 during the monitoring period.
Read the full article on GMJ Newsroom.
Was this article helpful?
